Moreover, the inhibition of leptin signaling could be a novel target for adjuvant drugs aimed to enhance efficacy of 5-FU, and other chemotherapeutics, which could be especially relevant for overweight and obese PC patients. The gene discussed is LEP; the disease is pachyonychia congenita.